论文部分内容阅读
人的免疫系统能识别人恶性黑色素瘤的细胞表面成份。仅少数黑色素瘤患者产生抗单一黑色素瘤抗原或高度限制黑素细胞分化抗原抗体。因此,可用血清限制抗原性的疫苗对黑色素瘤患者进行免疫,诱导机体产生相应抗体。17例Ⅱ期恶性黑色素瘤患者接受疫苗治疗,此疫苗用三种同种异体黑色素瘤细胞株制备,诱导人的免疫功能对抗黑色素瘤细胞表面抗原。病人在接种的同时未发生可见的黑色素瘤。疫苗用三种黑色素瘤细胞株制备,三种细胞株为高度表达限制黑素细胞分化的抗原.细胞株其中之一为仅在这种特殊细胞株中表达
The human immune system recognizes the cell surface components of human malignant melanoma. Only a few melanoma patients develop antibodies against a single melanoma antigen or a highly restricted melanocyte differentiation antigen. Therefore, patients with melanoma can be immunized with serum-limited antigenic vaccines to induce the body to produce antibodies. Seventeen patients with stage II malignant melanoma received vaccination. The vaccine was prepared from three allogeneic melanoma cell lines and induced human immune function against melanoma cell surface antigens. The patient did not develop visible melanoma at the same time as the inoculation. The vaccine was prepared with three melanoma cell lines, three of which are highly expressed antigens that limit melanocyte differentiation. One of the cell lines is expressed only in this particular cell line.